CLINICAL TRIALS PROFILE FOR VERINURAD

Clinical Trials for Verinurad

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT03118739 ↗	Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria	Completed	AstraZeneca	Phase 2	The purpose of this clinical research study is to evaluate signals of potential clinical benefit of the combination of Verinurad and Febuxostat in lowering concentrations of circulating uric acid and thus improving kidney or cardiovascular status of patients with hyperuricemia, albuminuria, and Type 2 diabetes (T2DM).
NCT03316131 ↗	A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA	Completed	Analytical Laboratory (Pharmacokinetic Sample Analysis): USA	Phase 2	This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat + dapagliflozin/placebo) and follow-up visit
NCT03316131 ↗	A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA	Completed	Clinical Laboratory: USA	Phase 2	This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat + dapagliflozin/placebo) and follow-up visit
NCT03316131 ↗	A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA	Completed	Contract Research Organization: USA	Phase 2	This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat + dapagliflozin/placebo) and follow-up visit
NCT03316131 ↗	A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA	Completed	Covance Bioanalytical Services, LLC	Phase 2	This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat + dapagliflozin/placebo) and follow-up visit

Clinical Trial Conditions for Verinurad

Condition Name

Condition Name for
Intervention	Trials
Chronic Kidney Disease	5
Type 2 Diabetes	1
Albuminuria	1
Asymptomatic Hyperuricemia	1

Condition MeSH

Condition MeSH for
Intervention	Trials
Renal Insufficiency, Chronic	7
Kidney Diseases	7
Hyperuricemia	3
Heart Failure	1

Clinical Trial Locations for Verinurad

Trials by Country

Trials by Country for
Location	Trials
United States	31
Germany	5
Canada	2
Poland	2
Mexico	2

Trials by US State

Trials by US State for
Location	Trials
California	5
Maryland	3
Virginia	2
North Carolina	2
Florida	2

Clinical Trial Progress for Verinurad

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 2	4
Phase 1	5

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	7
Active, not recruiting	2

Clinical Trial Sponsors for Verinurad

Sponsor Name

Sponsor Name for
Sponsor	Trials
AstraZeneca	9
Parexel	4
Covance Bioanalytical Services, LLC	1

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	13
Other	8